Will Pfizer Hit $100 This Year?
If winners keep winning, as the saying goes, then 2022 should be a great year for Pfizer (NYSE: PFE). The company has consistently delivered blowout financial results in recent quarters, thanks largely to its COVID-19 vaccine, Comirnaty. Investors have responded by bidding up Pfizer's shares; the company was one of the best-performing pharma giants in 2021.
But how will things turn out for Pfizer in 2022? Let's look at what's going on with this drugmaker and determine whether its shares can soar nearly 80% to be worth $100 by the end of this year.
Source Fool.com